Leadership
Ed Shenkan
Shenkan Advisor’s founder and CEO, is an experienced healthcare executive, FDA leader, corporate director and healthcare sell side financial analyst with a deep knowledge of public and private healthcare companies and an extensive network in the investment community. As a board member, he has provided counsel on strategic planning, M&A opportunities, exit strategies, financial modeling, raising capital, and product positioning. He has served in operational roles in sales management, marketing, and business development with Schering Plough, now Merck. He was the first associate director of FDA’s TAP innovation division of CDRH (FDA’s medical device and diagnostics division). While at FDA, he launched and directed the TAP division and consulting practice to help breakthrough products obtain reimbursement. Ed has been involved with the National Association of Corporate Directors and satisfies the SEC requirements to Chair a public company Audit Committee.
​
Boards and management teams call on Ed to conduct exit analysis including valuation and determining when and how to best exit a business or investment. These projects include capital allocation decisions including whether to: fund a clinical trial, invest in market development, pursue reimbursement for a procedure, enter new markets, or to partner or independently market a product. This analysis can help to gain agreement by the full Board or management team.
At Shenkan Advisors, Ed works with public and private healthcare companies to develop business strategy and analyze operational issues for management and the board. Ed has experience conducting due diligence, financial analysis, valuation, and identifying compelling sectors and companies for investment opportunities within the medical device, diagnostics, biopharma, and healthcare service industries. Ed also develops strategic marketing assessments for existing and new markets. These assessments include market size, penetration, growth, segmentation, and pricing. Ed surveys over a thousand physicians and interviews several hundred physicians, medical providers, medical facility administrators, and payors annually collecting voice of customer data. This qualitative and quantitative primary research is incorporated into his financial analysis and models.
Before founding Shenkan Advisors in 2009, Mr. Shenkan spent a decade as a sell side securities analyst for J.P. Morgan, Wells Fargo Securities, and Needham. Ed has authored medical device industry reports on Spine, Ophthalmology, Neurovascular, Radiation Therapy, Cardiovascular and Robotics companies and products. As a securities analyst Ed covered companies including American Medical Systems, ArthroCare, Biomet, Boston Scientific, Cardica, Cepheid, Cytyc, Digene, EPIX Pharmaceuticals, Gen-Probe, Given Imaging, Hansen, Hologic, Intuitive Surgical, Kyphon, LifeCell, Micrus Endovascular, Medtronic, Natus, NuVasive, OraSure, Rita Medical, Stereotaxis, Stryker, and Zoll Medical.
He earned an MBA from Duke University, a B.A. from the University of Pennsylvania, and a B.S. from The Wharton School.
Contact
(415) 309-5979
Shenkan Advisors
